Understanding Blood Test M C V Mean Diagnosis Anemia

Published

Table of Contents

The Mean Corpuscular Volume (MCV) is a critical metric in hematology that serves as a diagnostic cornerstone in evaluating anemia and other blood disorders. Derived from a Complete Blood Count (CBC), MCV quantifies the average size of red blood cells in femtoliter (fL) units, offering clinicians a precise tool to classify anemia subtypes and guide targeted interventions. Beyond its role in anemia diagnosis, MCV deviations—whether elevated (macrocytosis) or reduced (microcytosis)—provide actionable insights into underlying conditions, from nutritional deficiencies to chronic diseases. This analysis explores MCV’s clinical significance, its calculation methodology, and how its interpretation shapes differential diagnosis and treatment strategies.

MCV is calculated using a straightforward yet informative formula: (Hematocrit × 10) / Red Blood Cell Count (RBC), where hematocrit reflects the proportion of red blood cells in blood volume. For instance, a patient with a hematocrit of 36% and an RBC count of 4.5 million/µL yields an MCV of 80 fL, falling within the normocytic range for adults. However, variations in MCV—such as values below 80 fL (microcytic) or above 100 fL (macrocytic)—trigger further diagnostic pathways, including tests for iron, vitamin B12, or folate deficiencies. These deviations are not merely numerical anomalies but biomarkers of systemic health, often correlating with conditions like iron deficiency anemia (the most prevalent anemia globally, affecting ~1.6 billion people) or macrocytic disorders linked to alcoholism or liver disease.

blood test what does mcv mean

Mean Corpuscular Volume (MCV) in Blood Tests: Definition, Measurement, and Clinical Significance

The Mean Corpuscular Volume (MCV) is a critical parameter in a Complete Blood Count (CBC) test, providing insights into the size of red blood cells (RBCs) and aiding in the classification and diagnosis of anemia. As part of the erythrocyte indices, MCV is derived from hematocrit (Hct) and RBC count, offering a quantitative measure essential for distinguishing between microcytic, normocytic, and macrocytic anemias. Its clinical utility extends beyond anemia, influencing evaluations of nutritional deficiencies, bone marrow disorders, and hemolytic conditions. Understanding MCV involves interpreting its measurement unit (femtoliters, fL), recognizing its diagnostic thresholds, and applying its calculation formula to derive actionable insights from laboratory results.

Definition and Role of MCV in Complete Blood Count (CBC) Tests

The Mean Corpuscular Volume (MCV) represents the average volume of a single red blood cell, expressed in femtoliters (fL). It is calculated as part of the erythrocyte indices alongside Mean Corpuscular Hemoglobin (MCH) and Mean Corpuscular Hemoglobin Concentration (MCHC). In a CBC, MCV serves as a primary discriminator for anemia subtypes, guiding further diagnostic investigations. For instance:
  • A low MCV (<80 fL) suggests microcytic anemia, often linked to iron deficiency or thalassemia.
  • A normal MCV (80–100 fL) indicates normocytic anemia, potentially due to chronic disease or acute blood loss.
  • A high MCV (>100 fL) points to macrocytic anemia, commonly associated with vitamin B12 or folate deficiencies.

    • MCV’s role is foundational in hematological assessments, as it correlates with RBC production efficiency, hemoglobin synthesis, and underlying pathological mechanisms.

    Measurement Unit and Diagnostic Significance of MCV

    The femtoliter (fL) is the standard unit for MCV, derived from the cubic micrometer (µm³) conversion (1 fL = 10⁻¹⁵ L = 1 µm³). This unit quantifies the volume of a single RBC, with normal ranges varying by age and physiological state. Deviations from these ranges trigger targeted diagnostic pathways:
  • Microcytosis (MCV <80 fL) may indicate iron deficiency anemia (IDA), thalassemia, or chronic inflammation.
  • Macrocytosis (MCV >100 fL) often reflects vitamin B12/folate deficiency, liver disease, or alcohol-related anemia.
  • Normocytic MCV (80–100 fL) requires further evaluation for hemolytic anemia, aplastic anemia, or anemia of chronic disease (ACD).

    • The precision of MCV measurement relies on automated hematology analyzers, which calculate it using laser-based cell counting and electrical impedance methods. These techniques ensure accuracy within ±2 fL, critical for distinguishing subtle pathological shifts.

    Normal MCV Ranges Across Age Groups and Clinical Implications

    MCV values exhibit age-dependent variability, reflecting physiological differences in RBC production and maturation. Below is a structured comparison of normal MCV ranges and their clinical implications:
    Age Group Normal MCV Range (fL) Clinical Implications of Deviations
    Newborns (0–4 weeks) 95–115 fL
    • Physiologically elevated due to fetal hemoglobin (HbF) persistence; macrocytosis may normalize by 2 months.
    • Persistent macrocytosis (>120 fL) suggests congenital disorders (e.g., Diamond-Blackfan anemia) or maternal folate/B12 deficiency.
    • Microcytosis (<80 fL) is rare but may indicate iron deficiency or thalassemia trait.
    Infants (1–24 months) 70–95 fL
    • Lower baseline MCV due to transition from HbF to adult hemoglobin (HbA).
    • Microcytosis (<70 fL) warrants evaluation for iron deficiency (common in weaning infants) or α-thalassemia.
    • Macrocytosis (>100 fL) may reflect nutritional deficiencies or metabolic disorders (e.g., methylmalonic acidemia).
    Children (2–12 years) 76–96 fL
    • Stable range; deviations often linked to dietary deficiencies (iron, B12, folate) or chronic illnesses (e.g., celiac disease).
    • Microcytosis (<75 fL) in older children may indicate lead poisoning or thalassemia major.
    • Macrocytosis (>100 fL) requires assessment for liver disease or inherited bone marrow disorders.
    Adolescents (13–18 years) 80–100 fL
    • Approaches adult values; growth spurts may temporarily lower MCV due to increased RBC demand.
    • Persistent microcytosis (<80 fL) in females may signal menorrhagia-related iron loss.
    • Macrocytosis (>105 fL) in males may indicate alcohol use or myelodysplastic syndromes (MDS).
    Adults (19+ years) 80–100 fL
    • Microcytosis (<80 fL) is highly specific for iron deficiency or thalassemia; further testing includes serum ferritin, hemoglobin electrophoresis.
    • Macrocytosis (>100 fL) necessitates B12/folate levels, liver function tests (LFTs), and alcohol history.
    • Normocytic MCV with low RBC count may suggest hemolytic anemia or bone marrow suppression.
    Pregnant Women 80–96 fL (expanded plasma volume may lower MCV)
    • Physiological dilutional anemia (normocytic) is common; MCV <80 fL requires iron supplementation.
    • Macrocytosis (>100 fL) may reflect folate deficiency or hyperemesis gravidarum.
    Key Considerations:
  • Physiological variability: MCV may fluctuate with altitude, smoking, or recent blood transfusions.
  • Analytical interference: Cold agglutinins, lipemia, or hemolysis can skew MCV results, necessitating manual review of peripheral blood smears.
  • Therapeutic monitoring: MCV trends are critical in assessing response to iron therapy (IDA) or B12/folate supplementation (macrocytic anemia).

    • Calculation of MCV Using Hematocrit and RBC Count

    The MCV formula is derived from fundamental hematological principles, combining hematocrit (Hct) and Red Blood Cell (RBC) count to yield the average RBC volume. The formula is:
    MCV (fL) = (Hematocrit × 10) / Red Blood Cell Count (RBC × 10¹²/L)
    Step-by-Step Procedural Explanation:

    1. Obtain Hematocrit (Hct) and RBC Count:

  • Hct is expressed as a percentage (e.g., 4

    • blood test what does mcv mean - Ilustrasi 2

    Clinical Significance of Mean Corpuscular Volume (MCV) in Anemia Diagnosis

    The Mean Corpuscular Volume (MCV) serves as a critical diagnostic indicator in hematology, distinguishing between different types of anemia based on red blood cell (RBC) size. Abnormal MCV values—whether elevated (macrocytosis) or reduced (microcytosis)—correlate with distinct underlying pathologies, ranging from nutritional deficiencies to chronic diseases. Understanding these patterns enables targeted follow-up testing and tailored therapeutic interventions, improving patient outcomes. This section explores the clinical implications of MCV deviations, their associated conditions, and structured diagnostic pathways to guide differential diagnosis.

    Macrocytosis: Elevated MCV and Associated Medical Conditions

    Macrocytosis (MCV > 100 fL) reflects enlarged RBCs, often due to impaired DNA synthesis or membrane abnormalities. The severity of macrocytosis varies, with mild elevations (100–110 fL) potentially indicating early-stage deficiencies, while severe macrocytosis (>120 fL) may signal advanced or complex disorders. Below are key conditions linked to elevated MCV, categorized by severity and prevalence:

    - Mild Macrocytosis (MCV: 100–110 fL)

  • Alcoholism: Chronic alcohol abuse disrupts folate metabolism and impairs RBC maturation, contributing to macrocytosis in ~50–70% of cases. Liver dysfunction (e.g., fatty liver, cirrhosis) exacerbates folate deficiency, compounding the effect.
  • Early Vitamin B12/Folate Deficiency: Subclinical deficiencies (e.g., marginal folate intake or mild malabsorption) may present with isolated MCV elevation before hemoglobin (Hb) or reticulocyte count declines. Studies indicate ~10–20% of macrocytic anemias stem from folate deficiency alone.
  • Hypothyroidism: Thyroid hormone deficiency alters RBC membrane fluidity and erythropoietin sensitivity, leading to mild macrocytosis in ~20–30% of untreated cases.

    • - Moderate Macrocytosis (MCV: 110–120 fL)

  • Liver Disease (Chronic Hepatitis, Cirrhosis): Portal hypertension and impaired folate storage (e.g., reduced hepatic folate binding protein) contribute to macrocytosis in ~40–60% of patients. Alcohol-related liver disease (ALD) often co-occurs with folate/B12 deficiencies.
  • Medication-Induced: Drugs such as methotrexate, 5-fluorouracil, or proton pump inhibitors (PPIs) interfere with folate metabolism, causing macrocytosis in ~10–25% of long-term users. PPIs, prescribed to ~10% of the global population, may elevate MCV by ~5–10 fL in susceptible individuals.
  • Reticulocytosis: Accelerated RBC turnover (e.g., post-hemolytic anemia or hemolytic disorders) temporarily increases MCV due to young, larger reticulocytes comprising a higher proportion of the RBC population.

    • - Severe Macrocytosis (MCV > 120 fL)

  • Vitamin B12 Deficiency (Pernicious Anemia): Autoimmune atrophic gastritis (affecting ~1–5% of adults >60 years) impairs intrinsic factor production, leading to malabsorption and severe macrocytosis (MCV > 130 fL) with hypersegmented neutrophils. Untreated, it progresses to megaloblastic anemia with Hb < 8 g/dL.
  • Myelodysplastic Syndromes (MDS): Clonal hematopoietic stem cell disorders (e.g., refractory anemia subtype) present with macrocytosis in ~80–90% of cases, often accompanied by leukopenia and thrombocytopenia. MCV > 110 fL in MDS carries a ~30% higher risk of progression to acute myeloid leukemia (AML).
  • Rare Genetic Disorders: Congenital dyserythropoietic anemias (e.g., type II CDA) or inherited disorders of DNA repair (e.g., Fanconi anemia) may cause severe macrocytosis with additional cytopenias.

    • Microcytosis: Low MCV and Underlying Pathologies

    Microcytosis (MCV < 80 fL) indicates small RBCs, primarily resulting from impaired hemoglobin synthesis or increased RBC destruction. Among microcytic anemias, iron deficiency is the most prevalent worldwide, accounting for ~50–70% of cases in developing regions and ~20–30% in industrialized nations. Below are the primary causes, with a focus on iron deficiency and its epidemiological significance:
    Iron deficiency anemia (IDA) affects ~1.6 billion people globally, with prevalence rates exceeding 30% in women of reproductive age and ~20% in children under 5 years. Chronic blood loss (e.g., menstrual, gastrointestinal) and inadequate dietary intake (e.g., low heme iron) are the leading contributors. Microcytosis in IDA typically presents with MCV < 70 fL, Hb < 10 g/dL, and elevated red cell distribution width (RDW > 15%), reflecting variability in RBC size.
    Additional causes of microcytosis include:
  • Thalassemia Syndromes: Hemoglobinopathies (e.g., α-thalassemia, β-thalassemia) disrupt globin chain synthesis, leading to microcytic, hypochromic anemia. β-thalassemia minor (heterozygous) affects ~1.5% of the global population, with MCV often between 60–70 fL and target cells on peripheral smear.
  • Chronic Diseases (Anemia of Chronic Inflammation): Conditions such as rheumatoid arthritis, chronic kidney disease, or infections (e.g., tuberculosis) impair iron utilization via hepcidin-mediated blockade. Microcytosis (MCV 65–75 fL) coexists with normal or elevated ferritin levels, distinguishing it from IDA.
  • Lead Toxicity: Chronic exposure inhibits δ-aminolevulinic acid dehydratase (ALAD), disrupting heme synthesis. Microcytosis (MCV < 70 fL) is accompanied by basophilic stippling and elevated free erythrocyte protoporphyrin (FEP) levels.
  • Sideroblastic Anemias: Ineffective erythropoiesis due to mitochondrial dysfunction (e.g., acquired or hereditary) results in microcytic anemia with ringed sideroblasts on bone marrow biopsy. MCV typically ranges from 60–75 fL.

    • Diagnostic Pathways for Macrocytic vs. Microcytic Anemia

    The MCV-guided diagnostic approach streamlines the evaluation of anemia by prioritizing high-yield follow-up tests based on RBC morphology. Below is a comparative table outlining the primary and secondary tests for macrocytic and microcytic anemia, along with likely etiologies and treatment focuses:
    Macrocytic AnemiaMicrocytic Anemia
    Primary TestsPrimary Tests
    - Complete Blood Count (CBC) with RDW- CBC with RDW and peripheral smear
    - Serum folate and B12 levels- Serum ferritin and iron studies
    - Reticulocyte count- Total iron-binding capacity (TIBC)
    - Hemoglobin electrophoresis (if thalassemia suspected)
    Follow-Up TestsFollow-Up Tests
    - Anti-intrinsic factor antibodies (if B12 deficiency)- Stool occult blood test (for GI blood loss)
    - Liver function tests (LFTs)- Endoscopy/colonoscopy (if chronic blood loss)
    - Bone marrow biopsy (if MDS suspected)- Hepcidin levels (for anemia of chronic disease)
    - Thyroid-stimulating hormone (TSH)- Lead levels (if exposure risk)
    Likely CausesLikely Causes
    - Vitamin B12/folate deficiency- Iron deficiency anemia (IDA)
    - Alcohol-related liver disease- Thalassemia syndromes
    - Myelodysplastic syndromes (MDS)- Chronic disease (e.g., CKD, RA)
    - Hypothyroidism- Lead poisoning
    Treatment FocusTreatment Focus
    - Folate/B12 supplementation- Oral/IV iron therapy (IDA)
    - Alcohol cessation and liver support- Transfusion (severe thalassemia)
    - Hydroxyurea (for MDS)- Erythropoietin-stimulating agents (CKD)
    - Thyroid hormone replacement- Chelation therapy (lead toxicity)

    Flowchart: MCV-Driven Diagnostic Workflow for Anemia Evaluation

    The MCV result directs subsequent blood tests to

    blood test what does mcv mean - Ilustrasi 3

    Mean Corpuscular Volume (MCV) in Anemia Classification and Differential Diagnosis

    The Mean Corpuscular Volume (MCV) serves as a cornerstone in the classification and diagnostic approach to anemias, enabling clinicians to categorize disorders based on red blood cell (RBC) size and guide targeted investigations. By stratifying anemias into normocytic, microcytic, and macrocytic groups, MCV narrows differential diagnoses, reduces unnecessary testing, and informs therapeutic strategies. This structured classification is particularly critical in distinguishing between conditions with overlapping clinical presentations, such as iron deficiency anemia (IDA) and thalassemia, where laboratory markers beyond MCV—such as RBC distribution width (RDW), serum iron, and hemoglobin electrophoresis—refine diagnostic precision.

    MCV trends over time also provide prognostic insights, particularly in monitoring treatment response (e.g., iron supplementation in IDA) or disease progression (e.g., vitamin B12 deficiency in macrocytic anemias). Below, the MCV-based classification is detailed, followed by a comparative analysis of IDA and thalassemia, and a summary table of key anemias by MCV category, including diagnostic and treatment approaches.

    Classification of Anemias by MCV Ranges and Key Distinguishing Features

    Anemias are categorized by MCV into three primary groups, each associated with distinct etiologies and RBC morphology. This classification directs initial diagnostic workup and therapeutic planning. Below, the defining features of each MCV category are outlined, emphasizing morphological and laboratory hallmarks.
    MCV Reference Range:
  • Microcytic: <80 fL
  • Normocytic: 80–100 fL
  • Macrocytic: >100 fL
    • Microcytic Anemias (<80 fL)
    Microcytic anemias arise from impaired hemoglobin synthesis or increased RBC destruction, often due to iron deficiency, thalassemia, or chronic disease. Key distinguishing features include:
  • Hypochromic RBCs (reduced central pallor on peripheral smear) and target cells (in thalassemia).
  • Elevated RDW in iron deficiency (reflecting variable RBC size) vs. normal or low RDW in thalassemia (uniform microcytosis).
  • Low serum ferritin (iron deficiency) vs. normal/high ferritin with low serum iron (anemia of chronic disease).

    • Normocytic Anemias (80–100 fL)
    Normocytic anemias typically indicate acute blood loss, hemolytic processes, or early-stage chronic diseases. Distinguishing features include:

  • Normal MCV with reticulocytosis (hemolytic anemia) or low reticulocyte count (aplastic anemia).
  • Spherocytes (hereditary spherocytosis) or schistocytes (microangiopathic hemolytic anemia).
  • Elevated lactate dehydrogenase (LDH) and indirect bilirubin in hemolytic anemias.

    • Macrocytic Anemias (>100 fL)
    Macrocytic anemias are primarily caused by DNA synthesis defects (vitamin B12/folate deficiency) or liver disease/alcoholism. Key features include:

  • Oval macrocytes (vitamin B12/folate deficiency) or giant platelets (myelodysplastic syndromes).
  • Elevated methylmalonic acid (MMA) and homocysteine (B12 deficiency) vs. normal MMA (folate deficiency).
  • Hypersegmented neutrophils (megaloblastic changes in bone marrow).

    • Differentiating Iron Deficiency Anemia (IDA) and Thalassemia Using MCV and Supporting Markers

    Iron deficiency anemia and thalassemia share microcytic, hypochromic RBCs and symptoms like fatigue and pallor, but their underlying mechanisms and laboratory profiles differ significantly. MCV, combined with RDW, serum iron studies, and hemoglobin electrophoresis, resolves this differential diagnosis.

    Overlapping Features:

  • Microcytic, hypochromic anemia (MCV <80 fL).
  • Symptoms: Fatigue, dyspnea, pica (IDA), or splenomegaly (thalassemia).
  • Peripheral smear: Target cells (thalassemia) vs. pencil cells (IDA).

    • Distinguishing Markers:

    ParameterIron Deficiency Anemia (IDA)Thalassemia
    RDWElevated (>15%) due to variable RBC size.Normal or low (<15%) due to uniform microcytosis.
    Serum FerritinLow (<15 ng/mL) or depleted iron stores.Normal/high (unless coexistent iron deficiency).
    Serum Iron & TIBCLow iron, high TIBC (transferrin saturation <15%).Normal/high iron, normal TIBC.
    Hemoglobin ElectrophoresisNormal (unless coexistent hemoglobinopathy).Abnormal (e.g., HbA2 >3.5% in β-thalassemia).
    Bone Marrow FindingsDepleted iron stores (absent stainable iron).Erythroid hyperplasia with ineffective erythropoiesis.
    Diagnostic Algorithm:
    1. Elevated RDW + low ferritin → IDA (confirm with serum iron/TIBC).
    2. Normal RDW + normal/high ferritin → Thalassemia (confirm with Hb electrophoresis).
    3. Overlap cases (e.g., IDA + thalassemia trait) require genetic testing or trial iron therapy (MCV normalization suggests IDA).

    Summary Table of Top 3 Anemias by MCV Category

    Below is a comparative table of the most common anemias within each MCV category, including key laboratory findings and initial treatment approaches.
    Anemia Type MCV Range (fL) Key Lab Findings Beyond MCV Initial Treatment Approach
    Iron Deficiency Anemia (IDA) <80
    • Low serum ferritin (<15 ng/mL), low serum iron, high TIBC.
    • Elevated RDW (>15%), hypochromic microcytic RBCs.
    • Normal HbA2/electrophoresis (unless coexistent thalassemia).
    • Oral iron supplementation (ferrous sulfate/gluconate).
    • IV iron (severe/malabsorption). Address underlying cause (e.g., GI bleed, poor diet).
    β-Thalassemia Major/Intermedia <80
    • Normal/high ferritin, normal/high serum iron, low TIBC.
    • Low RDW, target cells, basophilic stippling.
    • HbA2 >3.5%, HbF elevated (β-thalassemia).
    • Regular blood transfusions (thalassemia major).
    • Iron chelation (deferoxamine/desferrioxamine).
    • Hematopoietic stem cell transplant (curative for severe cases).
    Vitamin B12 Deficiency (Pernicious Anemia) >100
    • Elevated methylmalonic acid (MMA) and homocysteine.
    • Hypersegmented neutrophils, oval macrocytes.
    • Positive intrinsic factor antibodies (pernicious anemia).
    • Parenteral vitamin B12 (hydroxocobalamin) if malabsorption.
    • Oral B12 if dietary deficiency (less common).
    • Monitor MMA

      MCV emerges as a linchpin in hematological assessment, bridging laboratory data with clinical decision-making. Its ability to categorize anemia—whether normocytic, microcytic, or macrocytic—streamlines diagnostic precision, reducing reliance on invasive or costly tests. For example, a microcytic MCV (<80 fL) with elevated RDW and low serum iron points decisively toward iron deficiency anemia, while a macrocytic MCV (>100 fL) accompanied by hypersegmented neutrophils may indicate vitamin B12 deficiency. Monitoring MCV trends over time further refines prognosis, such as observing an upward shift in MCV during iron therapy for iron deficiency anemia, which signals improving erythropoiesis. Ultimately, MCV is more than a passive measurement; it is an active guide in personalized medicine, enabling clinicians to tailor interventions with evidence-based accuracy.

      FAQ

      What does MCV mean in a blood test?

      MCV stands for Mean Corpuscular Volume, which measures the average size of your red blood cells. It’s part of a Complete Blood Count (CBC) and helps diagnose conditions like anemia by indicating whether red blood cells are too large (macrocytic), too small (microcytic), or normal (normocytic).

      What does a high MCV level in a blood test mean?

      A high MCV (above ~100 fL) suggests macrocytic anemia, often caused by vitamin B12 or folate deficiency, liver disease, alcohol misuse, or certain medications. It can also occur in pregnancy or after recent blood transfusions. Further tests (like B12/folate levels) are usually needed to pinpoint the cause.

      What does a low MCV level in a blood test mean?

      A low MCV (below ~80 fL) indicates microcytic anemia, commonly linked to iron deficiency, thalassemia, or chronic disease (e.g., inflammation). Less often, it may signal lead poisoning or sideroblastic anemia. Iron studies (ferritin, TIBC) help determine the underlying issue.

      In a CBC blood test, what does MCV stand for and what does it measure?

      In a CBC (Complete Blood Count), MCV stands for Mean Corpuscular Volume and measures the average volume of a single red blood cell. It’s calculated by dividing the hematocrit (Hct) by the red blood cell count (RBC) and helps classify anemia by red blood cell size (microcytic, normocytic, or macrocytic).

      What does MCV mean in lab work?

      In lab work, MCV (Mean Corpuscular Volume) is a red blood cell index that quantifies the size of your red blood cells in femtoliter (fL) units. It’s derived from a CBC and is critical for diagnosing types of anemia—abnormal MCV values guide further testing (e.g., iron, B12, or folate levels).

      What is the meaning of MCV in a blood test in Tamil?

      MCV (Mean Corpuscular Volume) in a blood test is called "செல்கள் சராசரி அளவு" (cell sarasari alavu) in Tamil. இது இரத்த சிவப்பணுக்களின் (iratha chivappaṇukkalin) சராசரி அளவைக் காட்டுகிறது (*sarāsari alavukai kāṭṭukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukirattukir

      Leave a Comment

      Comments are moderated before appearing. The data you submit is processed according to the Privacy Policy of Voltefac.